Brief: Zenas Biopharma And Royalty Pharma Enter Into Obexelimab Funding Agreement For Up To $300 Million
02/09/2025 13:40
Royalty Pharma PLC RPRX.O: ZENAS BIOPHARMA AND ROYALTY PHARMA ENTER INTO OBEXELIMAB FUNDING AGREEMENT FOR UP TO $300 MILLION ROYALTY PHARMA PLC - INITIAL $75 MILLION TO FUND U.S. LAUNCH OF OBEXELIMAB ROYALTY PHARMA PLC - TO RECEIVE 5.5% ROYALTY ON OBEXELIMAB SALES Source text: ID:nGNX3Gl7Kv Further company coverage: RPRX.O
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)